Relay Therapeutics, Inc.
RLAYNASDAQHealthcare● Active
$13.72
+$0.20(+1.48%)
Market Cap$2.4B
P/E Ratio—
52W High$17.47
52W Low$2.98
Relay Therapeutics, Inc. (RLAY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RLAY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M |
| Cost of Revenue | $3.56M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $11.80M | $10.01M | $25.55M | $1.38M | $3.03M |
| Gross Margin %(computed) | 76.83% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $261.38M | $319.09M | $330.02M | $246.35M | $172.65M |
| G&A Expenses | $56.71M | $76.59M | $74.95M | $65.98M | $57.39M |
| Total Operating Expenses | $314.54M | $382.48M | $398.55M | $300.66M | $367.73M |
| Operating Income | ($302.74M) | ($372.47M) | ($373.00M) | ($299.27M) | ($364.70M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $27.04M | $34.75M | $31.05M | $8.79M | $0.83M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($276.48M) | ($337.71M) | ($341.97M) | ($290.51M) | ($363.87M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($276.48M) | ($337.71M) | ($341.97M) | ($290.51M) | ($363.87M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| Wtd Avg Shares | 171.59M | 142.87M | 122.58M | 112.23M | 95.14M |
| EBITDA | ($272.92M) | ($380.21M) | ($374.15M) | ($306.82M) | ($223.08M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Relay Therapeutics, Inc. data
About Relay Therapeutics, Inc. (RLAY) Income Statement
Relay Therapeutics, Inc. (RLAY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RLAY reported revenue of $0.02B, gross profit of $0.01B (gross margin 76.83%), and net income of ($0.28B) — a net profit margin of -1800.58%.
Frequently asked questions
RLAY · 4 questionsRelay Therapeutics, Inc. (RLAY) reported revenue of $0.02B for 2025, up 53.4% year-over-year.
RLAY revenueRLAY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08